ViaLongeVita

Internal Medicine

This article was automatically translated into your selected language.(mymemory)

Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparVIP

Nature Medicine, Published online: 01 September 2026; doi:10.1038/s41591-026-04565-6 The phase 3 NSABP B-59/GeparDouze trial, in which patients with early-stage triple-negative breast cancer received neoadjuvant chemotherapy with or without atezolizumab, did not meet its primary endpoint of event-free survival, and com

MedScopeGlobal Editorial

1 September 2026

Content is not medical diagnosis or treatment advice. Always consult your physician.

Illustration for "Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/Gepar" — longevity and healthy aging, diverse group of adults

Enjoying this article? Support the editorial team with a tip

Nature Medicine, Published online: 01 September 2026; doi:10.1038/s41591-026-04565-6 The phase 3 NSABP B-59/GeparDouze trial, in which patients with early-stage triple-negative breast cancer received neoadjuvant chemotherapy with or without atezolizumab, did not meet its primary endpoint of event-free survival, and com

Exkluzivně pro předplatitele

Pokračujte ve čtení s MedScope Premium

VIP články obsahují klinické dopady, klíčové body a ověřené zdroje — navržené pro studenty a lékaře.

14 dní zkušební verze zdarma — vyzkoušejte bez rizika

Již máte účet? Přihlásit se · Srovnání tarifů

Support the author (MedScopeGlobal Editorial) · Tip

Optional micro-contribution — like a tip. Funds ViaLongeVita editorial.

A tip is not a VIP subscription and does not unlock paid content — it is optional support for the desk.

Contribution

Donate

A micro-donation helps us keep publishing quality content.

Recommended content

Articles

Prepared by the MedScopeGlobal.com editorial team — educational health content for the public. Always consult a physician for personal medical decisions.